Total
0
Shares
Theratechnologies - Chief Medical Officer and Senior Vice President Dr. Christian Marsolais
Chief Medical Officer and Senior Vice President Dr. Christian Marsolais
Source: Theratechnologies Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Theratechnologies Inc. (TH) reports its novel peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and triple negative breast cancer models
  • The PDCs, TH1902 and TH1904, are derived from the company’s SORT1+ Technology
  • SORT1 is a receptor that plays a significant role in protein internalization, sorting and trafficking
  • These results further support the expectation that TH1902 and TH1904 may alter the VM process by bringing anticancer drugs, like docetaxel and doxorubicin, into SORT1-positive cancer cells
  • Theratechnologies Inc. (TH) is down 1.595 per cent and is trading at $4.32 per share at 3:30 p.m. ET

Theratechnologies (TH) reports its investigational peptide-drug conjugates (PDCs) are effective in inhibiting vasculogenic mimicry (VM) in ovarian and breast cancer models.

VM is believed to be associated with tumour growth, resistance and poor prognosis in many types of aggressive cancers including ovarian and TNBC.

The PDCs, TH1902 and TH1904, are derived from the company’s SORT1+ Technology.

SORT1 is a receptor that plays a significant role in protein internalization, sorting and trafficking. It is highly expressed in cancer cells compared to healthy tissue making it an attractive target for cancer drug development.

According to Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, the results showcase [or the first time] the sortilin receptor plays a role in the formation of VM which is associated with cancer progression and resistance.

By targeting SORT1 the PDC’s have the potential to inhibit VM and cancer growth.

“This recognition by our scientific peers highlights the great potential of our PDCs as a unique and effective vehicle for the potential treatment of many types of cancers in which SORT1 receptors are overexpressed and provides additional evidence that SORT1 plays a major role in the generation of VM, particularly in TNBC and ovarian cancer,” said Dr. Marsolais.

These results further support the expectation that TH1902 and TH1904 may alter the VM process by bringing anticancer drugs, like docetaxel and doxorubicin, into SORT1-positive cancer cells.

Theratechnologies Inc. (TH) is down 1.595 per cent and is trading at $4.32 per share at 3:30 p.m. ET.

More From The Market Herald
LexaGene - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) closes multiple MiQLab sales

LexaGene (LXG) has received purchase orders from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke.
The Market Herald Video

" FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models

FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS.
The Market Herald Video

" Adastra Holdings (CSE:XTRX) reports record third-quarter results

Adastra Holdings (XTRX) has filed its consolidated financial statements and related MD&A for the three and nine months ended September 30, 2021, and 2020.